If you have been reading about metabolic research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
=== The molecular clock and the units of time === Typically, a branch length of a phylogenetic tree is expressed as the expected number of substitutions per site; if the evolutionary model indicates that each site within an ancestral sequence will typically experience x substitutions by the time it evolves to a particular descendant's sequence then the ancestor and descendant are considered to be separated by branch length x. Sometimes a branch length is measured in terms of geological years. For example, a fossil record may make it possible to determine the number of years between an ancestral species and a descendant species. Because some species evolve at faster rates than others, these two measures of branch length are not always in direct proportion. The expected number of substitutions per site per year is often indicated with the Greek letter mu (μ). A model is said to have a strict molecular clock if the expected number of substitutions per year μ is constant regardless of which species' evolution is being examined. An important implication of a strict molecular clock is that the number of expected substitutions between an ancestral species and any of its present-day descendants must be independent of which descendant species is examined. Note that the assumption of a strict molecular clock is often unrealistic, especially across long periods of evolution. For example, even though rodents are genetically very similar to primates, they have undergone a much higher number of substitutions in the estimated time since divergence in some regions of the genome.
In 1986 and 1987, Transkei, a larger, wealthier, and more populous entity, undertook a series of military raids on Ciskei, and attempted to seize control of Ciskei. One of these raids was an attack on leader Lennox Sebe's compound, with the apparent goal of taking him hostage, in order to force a merger of the two Bantustans. Transkei had previously granted sanctuary to Lennox Sebe's estranged brother, Charles, the former head of Ciskei's security forces, who had been imprisoned in Ciskei on charges of sedition, in addition to previously kidnapping Lennox Sebe's son. The South African government ostensibly intervened to warn the Transkei government off. However, during a later meeting of the Truth and Reconciliation Commission, it was revealed that the plan to amalgamate the Transkei and Ciskei into a proposed Xhosaland, as well as the freeing of Charles Sebe from prison, had been carried out by South African security forces linked to the Civil Cooperation Bureau, in order to consolidate an anti-ANC front in the Eastern Cape region, as part of the abortive Operation Katzen.
Ultrafiltration is the most hardware demanding option for protein recovery although it serves more as a protein concentration step rather than complete recovery. Chromatographic methods may be used in tandem with ultrafiltration to help increase solute mass and subsequent recovery. Solvent precipitation is not often reported although it produces the highest protein recovery among other methods and preserves the nutritional integrity of the LPC. The extraction and purification methods are largely inter-compatible and may be employed depending on local facilities. Interestingly, the purity of the final LPC was influenced by the protein content in the initial leaf mass rather than the purification method employed. Furthermore, the amino acid composition of the LPC was dependent on the extraction method employed. In laboratory conditions, protein fractions of 96% purity could be produced with a recovery of 56% w/w and an overall yield of 5.5%. Telek on the other hand experimented with numerous tropical plants at a large scale using a combination of pulping and heat coagulation. Yields were around 3% with protein recoveries <50%. Depending on the purity of the recovered protein, they are either called leaf protein extract (<60% w/w), leaf protein concentrate (>60% w/w), or leaf protein isolate (>90% w/w), although publications use these terms interchangeably.
== Portal site mediated adsorption == Portal site mediated adsorption is a model for site-selective activated gas adsorption in metallic catalytic systems that contain a variety of different adsorption sites. In such systems, low-coordination "edge and corner" defect-like sites can exhibit significantly lower adsorption enthalpies than high-coordination (basal plane) sites. As a result, these sites can serve as "portals" for very rapid adsorption to the rest of the surface. The phenomenon relies on the common "spillover" effect (described below), where certain adsorbed species exhibit high mobility on some surfaces. The model explains seemingly inconsistent observations of gas adsorption thermodynamics and kinetics in catalytic systems where surfaces can exist in a range of coordination structures, and it has been successfully applied to bimetallic catalytic systems where synergistic activity is observed. In contrast to pure spillover, portal site adsorption refers to surface diffusion to adjacent adsorption sites, not to non-adsorptive support surfaces. The model appears to have been first proposed for carbon monoxide on silica-supported platinum by Brandt et al. (1993). A similar, but independent model was developed by King and co-workers to describe hydrogen adsorption on silica-supported alkali promoted ruthenium, silver-ruthenium, and copper-ruthenium bimetallic catalysts. The same group applied the model to CO hydrogenation (Fischer–Tropsch synthesis). Zupanc et al.
Sources: en.wikipedia.org
Bush's legacy continues to develop, as time allows the development of a more nuanced historical perspective. Supporters credit his counterterrorism policies with preventing another major terrorist attack in the U.S. after September 11 and praise policies such as the Medicare prescription drug benefit and the AIDS relief program known as PEPFAR. Critics point to his handling of the Iraq War, specifically the failure to find weapons of mass destruction after claiming they were in Iraq, as well as Bush's handling of tax policy, Hurricane Katrina, climate change and the 2008 financial crisis, as proof he was unfit to be president. Ben Ferencz, chief prosecutor for the US Army at the Nuremberg Trials, stated that Bush likely committed war crimes in relation to the Iraq War. Several historians and commentators hold that Bush was one of the most consequential presidents in American history. Julian Zelizer described Bush's presidency as a "transformative" one, and said that "some people hate him, some people love him, but I do think he'll have a much more substantive perception as time goes on". Bryon Williams of The Huffington Post referred to Bush as "the most noteworthy president since FDR" and said the Patriot Act "increased authority of the executive branch at the expense of judicial opinions about when searches and seizures are reasonable" as evidence. Bush's administration presided over the largest tax cuts since the presidency of Ronald Reagan, and his homeland security reforms proved to be the most significant expansion of the federal government since the Great Society.
=== New lethal injection protocols === The Ohio protocol, developed after the incomplete execution of Romell Broom, aims to ensure the rapid and painless onset of anesthesia by only using sodium thiopental and eliminating the use of Pavulon and potassium as the second and third drugs, respectively. It also provides for a secondary fail-safe measure using intramuscular injection of midazolam, followed by sufentanil or hydromorphone, in the event intravenous administration of the sodium thiopental proves problematic. The first state to switch to use midazolam as the first drug in a new three-drug protocol was Florida on October 15, 2013. Then on November 14, 2013, Ohio made the same move.
==== Rookie of the Year Award and early career (1991–1993) ==== The Astros invited Bagwell to major league camp in spring training of 1991. Bagwell, expecting for the club to assign him to their Triple-A affiliate in Tucson, enthused them with his play. Because they, too, already had an established major leaguer at third base in Ken Caminiti, they approached Bagwell about shifting to first base, which he accepted. Having not previously played the position as a regular, Bagwell received a crash course, playing minor league games in the morning and Astros games in the afternoon until Opening Day. Observed The Sporting News: "Rookie Jeff Bagwell never played first base before this spring, but the position is his to lose. It's up to his bat." Thus, Bagwell made the major league club without an assignment to AAA, making the uncommon jump from AA to the major leagues, and made his major league debut on Opening Day. On May 6, he hit the ninth-ever upper-deck home run at Three Rivers Stadium off Bob Kipper in a seventh-inning pinch hit appearance, estimated at 456 feet (139 m). Bagwell hit .350 in September. He finished the year hitting .294 with 15 home runs and 82 RBI while leading the Astros in several offensive categories. He was named the 1991 National League (NL) Rookie of the Year, the first Astros player to win the award, Baseball America's Rookie of the Year, The Sporting News Rookie of the Year and postseason All-Star and on the Topps' Rookie All-Star Team. Bagwell's power hike piqued the curiosity of many baseball observers.
Sources: en.wikipedia.org
It remains under study whether phytoestrogens have any effect on male reproductive physiology. Some studies showed that isoflavone supplementation had a positive effect on sperm concentration, count, or motility, and increased ejaculate volume. Dietary intake of isoflavones at levels greater than in typical Asian diets does not affect estrogen, testosterone, sperm or semen amounts. Reviews of available studies found no link of phytoestrogens on male fertility, and instead indicate that diets, such as the Mediterranean diet, might have a positive effect on male fertility. Neither isoflavones nor soy have been shown to affect male reproductive hormones in healthy individuals.
=== Availability === Midazolam is available in the United States as a syrup or as an injectable solution. Dormicum brand midazolam is marketed by Roche as white, oval, 7.5 mg tablets in boxes of two or three blister strips of 10 tablets, and as blue, oval, 15 mg tablets in boxes of two (Dormonid 3x) blister strips of 10 tablets. The tablets are imprinted with "Roche" on one side and the dose of the tablet on the other side. Dormicum is also available as 1, 3, and 10 mL ampoules at a concentration of 5 mg/mL. Another manufacturer, Novell Pharmaceutical Laboratories, makes it available as Miloz in 3 and 5 mL ampoules. Midazolam is the only water-soluble benzodiazepine available. Another maker is Roxane Laboratories; the product in an oral solution, midazolam HCl Syrup, 2 mg/mL clear, in a red to purplish-red syrup, cherry in flavor. It becomes soluble when the injectable solution is buffered to a pH of 2.9–3.7. Midazolam is also available in liquid form. It can be administered intramuscularly, intravenously, intrathecally, intranasally, buccally, or orally.
== Psychoactive properties == Laussmann & Meier-Giebing (2010) reported the presence of psilocybin at ~2.5% and psilocin at ~1.194% from 25 samples seized by the German government, which makes modern commercially cultivated strains of this fungus the most potent hallucinogenic mushrooms ever described in published academic research. Other researchers have documented a significant presence of serotonin and urea in this species as well as the possibly psychoplastogenic indole alkaloid baeocystin.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.